Prevention and treatment of congenital toxoplasmosis

References

• Gilbert RE, Dunn DT, Lightman S et al. Incidence of symptomatic toxoplasma eye disease: aetiology and public health implications. Epidemiol. Infect.123(2), 283–289 (1999).
   PubMed Web of Science ®Google Scholar
• Gilbert R, Tan HK, Cliffe S, Guy E, Stanford M. Symptomatic toxoplasma infection due to congenital and postnatally acquired infection. Arch. Dis. Child.91(6), 495–498 (2006). (Erratum in: Arch. Dis. Child.91(7), 625 [2006]).
   PubMed Web of Science ®Google Scholar
• Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am. J. Ophthalmol.136(6), 973–988 (2003).
   PubMed Web of Science ®Google Scholar
• Bowie WR, King AS, Werker DH et al. Outbreak of toxoplasmosis associated with municipal drinking water. The BC Toxoplasma Investigation Team. Lancet350(9072), 173–177 (1997).
   PubMed Web of Science ®Google Scholar
• Bahia-Oliveira LM, Jones JL, Azevedo-Silva J, Alves CC, Orefice F, Addiss DG. Highly endemic, waterborne toxoplasmosis in north Rio de Janeiro state, Brazil. Emerg. Infect. Dis.9(1), 55–62 (2003).
   PubMed Web of Science ®Google Scholar
• Stanford MR, Tan HK, Gilbert R. Toxoplasmic retinochoroiditis presenting in childhood: clinical findings in a UK survey. Br. J. Ophthalmol.90(12), 1464–1467 (2006).
   PubMed Web of Science ®Google Scholar
• Dubey JP. Sources of Toxoplasma gondii infection in pregnancy. Until rates of congenital toxoplasmosis fall, control measures are essential. Br. Med. J.321, 127–128 (2000).
   PubMed Web of Science ®Google Scholar
• Hill D, Dubey JP. Toxoplasma gondii: transmission, diagnosis and prevention. Clin. Microbiol. Infect.8, 634–640 (2002).
   PubMed Web of Science ®Google Scholar
• Frenkel JK, Ruiz A, Chinchilla M. Soil survival of toxoplasma oocysts in Kansas and Costa Rica. Am. J. Trop. Med. Hyg.24, 439–443 (1975).
   PubMed Web of Science ®Google Scholar
• Kapperud G, Jenum PA, Stray-Pedersen B, Melby KK, Eskil A, Eng J. Risk factors for Toxoplasma gondii infection in pregnancy. Results of a prospective case–control study in Norway. Am. J. Epidemiol.144, 405–412 (1996).
   PubMed Web of Science ®Google Scholar
• Buffolano W, Gilbert RE, Holland FJ, Fratta D, Palumbo F, Ades AE. Risk factors for recent toxoplasma infection in pregnant women in Naples. Epidemiol. Infect.116, 347–351 (1996).
   PubMed Web of Science ®Google Scholar
• Baril L, Ancelle T, Goulet V, Thulliez P, Tirard-Fleury V, Carme B. Risk factors for Toxoplasma infection in pregnancy: a case–control study in France. Scand. J. Infect. Dis.31, 305–309 (1999).
   PubMedGoogle Scholar
• Cook AJ, Gilbert RE, Buffolano W et al. Sources of toxoplasma infection in pregnant women: European multicentre case–control study. European Research Network on Congenital Toxoplasmosis. Br. Med. J.321, 142–147 (2000).
   PubMed Web of Science ®Google Scholar
• Dubey JP, Hill DE, Jones JL et al. Prevalence of viable Toxoplasma gondii in beef, chicken, and pork from retail meat stores in the United States: risk assessment to consumers. J. Parasitol.91(5), 1082–1093 (2005).
   PubMed Web of Science ®Google Scholar
• Kotula AW, Dubey JP, Sharar AK, Andrew CD, Shen SK, Lindsay DA. Effect of freezing on infectivity of Toxoplasma gondii tissue cysts in pork. J. Food Protection54, 687–690 (1991).
   PubMed Web of Science ®Google Scholar
• Kijlstra A, Eissen OA, Cornelissen J, Munniksma K, Eijck I, Kortbeek T. Toxoplasma gondii infection in animal-friendly pig production systems. Invest. Ophthalmol. Vis. Sci.45(9), 3165–3169 (2004).
   PubMed Web of Science ®Google Scholar
• Conyn-van Spaedonck MA, van Knapen F. Choices in preventive strategies: experience with the prevention of congenital toxoplasmosis in The Netherlands. Scand. J. Infect. Dis.84(Suppl.), 51–58 (1992).
   Google Scholar
• Lopez A, Dietz VJ, Wilson M, Navin TR, Jones JL. Preventing congenital toxoplasmosis. MMWR Recomm. Rep.49(RR-2), 59–68 (2000).
   PubMedGoogle Scholar
• Breugelmans M, Naessens A, Foulon W. Prevention of toxoplasmosis during pregnancy – an epidemiologic survey over 22 consecutive years. J. Perinat. Med.32(3), 211–214 (2004).
   PubMed Web of Science ®Google Scholar
• Forsgren M, Gille E, Ljungstrom I, Nokes DJ. Toxoplasma gondii antibodies in pregnant women in Stockholm in 1969, 1979, and 1987. Lancet337(8754), 1413–1414 (1991).
   PubMed Web of Science ®Google Scholar
• Welton NJ, Ades AE. A model of toxoplasmosis incidence in the UK: evidence synthesis and consistency of evidence. JRSS (C) Applied Statistics54, 385–404 (2005).
   Google Scholar
• Remington JS, McLeod R, Thulliez P. Toxoplasmosis. In: Infectious Diseases of the Fetus and Newborn Infant. Remington JS, Klein J (Eds). WB Saunders, PA, USA 205–346 (2001).
   Google Scholar
• Wallon M, Liou C, Garner P, Peyron F. Congenital toxoplasmosis: systematic review of evidence of efficacy of treatment in pregnancy. Br. Med. J.318(7197), 1511–1514 (1999).
   PubMed Web of Science ®Google Scholar
• Gras L, Wallon M, Pollak A et al for the European Multicenter Study on Congenital Toxoplasmosis. Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. Acta Paediatr.94(12), 1721–1731 (2005).
   Google Scholar
• Gilbert R, Gras L, European Multicentre Study on Congenital Toxoplasmosis. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii.BJOG110, 12–120 (2003).
   PubMedGoogle Scholar
• The SYROCOT (Systematic Review on Congenital Toxoplasmosis) Study Group. Individual patient data meta-analysis of prenatal treatment effect for congenital toxoplasmosis. Lancet369, 115–122 (2007).
   PubMed Web of Science ®Google Scholar
• Aspock H, Pollak A. Prevention of prenatal toxoplasmosis by serological screening of pregnant women in Austria. Scand. J. Infect. Dis. (Suppl. 84), 32–37 (1992).
   Google Scholar
• Binquet C, Wallon M, Metral P, Gadreau M, Quantin C, Peyron F. Toxoplasmosis seroconversion in pregnant women. The differing attitudes in France. Presse Med.33, 775–779 (2004).
   PubMedGoogle Scholar
• Thalib L, Gras L, Romand S et al. Prediction of congenital toxoplasmosis by polymerase chain reaction analysis of amniotic fluid. Br. J. Obstet. Gynaecol.112(5), 567–574 (2005).
   Google Scholar
• Romand S, Chosson M, Franck J et al. Usefulness of quantitative polymerase chain reaction in amniotic fluid as early prognostic marker of fetal infection with Toxoplasma gondii.Am. J. Obstet. Gynecol.190(3), 797–802 (2004).
   PubMed Web of Science ®Google Scholar
• Logar J, Petrovec M, Novak-Antolic Z et al. Prevention of congenital toxoplasmosis in Slovenia by serological screening of pregnant women. Scand. J. Infect. Dis.34, 201–204 (2002).
   PubMed Web of Science ®Google Scholar
• Foulon W, Villena I, Stray-Pedersen B et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children’s sequelae at age 1 year. Am. J. Obstet. Gynecol.180, 410–415 (1999).
   PubMed Web of Science ®Google Scholar
• Freeman K, Oakley L, Pollak A et al for the European Multicentre Study on Congenital Toxoplasmosis (EMSCOT). Association between congenital toxoplasmosis and preterm birth, low birthweight and small for gestational age. Br. J. Obstet. Gynaecol.112, 31–37 (2005).
   Google Scholar
• Roizen N, Kasza K, Karrison T et al. Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics118(2), E379–E390 (2006).
   PubMed Web of Science ®Google Scholar
• Guerina NG, Hsu HW, Meissner HC et al. Neonatal serologic screening and early treatment for congenital T. gondii infection. The New England Regional Toxoplasma Working Group. N. Engl. J. Med.330, 1858–1863 (1994).
   PubMed Web of Science ®Google Scholar
• Lebech M, Andersen O, Christensen NC et al; Danish Congenital Toxoplasmosis Study Group. Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Lancet353, 1834–1837 (1999).
   PubMedGoogle Scholar
• Neto EC, Rubin R, Schulte J, Giugliani R. Newborn screening for congenital infectious diseases. Emerg. Infect. Dis.10, 1068–1073 (2004).
   PubMedGoogle Scholar
• Schmidt DR, Hogh B, Andersen O, Fuchs J, Fledelius H, Petersen E. The national neonatal screening programme for congenital toxoplasmosis in Denmark: results from the initial four years, 1999–2002. Arch. Dis. Child.91(8), 661–665 (2006).
   PubMed Web of Science ®Google Scholar
• Decoster A, Darcy F, Caron A et al. Anti-P30 IgA antibodies as prenatal markers of congenital toxoplasma infection. Clin. Exp. Immunol.87, 310–315 (1992).
   PubMed Web of Science ®Google Scholar
• Paul M, Petersen E, Szczapa J. Prevalence of congenital Toxoplasma gondii infection among newborns from the Poznan region of Poland: validation of a new combined enzyme immunoassay for Toxoplasma gondii-specific immunoglobulin A and immunoglobulin M antibodies. J. Clin. Microbiol.39, 1912–1916 (2001).
   PubMed Web of Science ®Google Scholar
• Janitschke K. Official recommendations and strategy for prevention of congenital toxoplasmosis in Germany. Arch. Pediatr.10(Suppl.), 15 (2003).
   PubMedGoogle Scholar
• Joynson DH. Congenital toxoplasma infection in the UK. Arch. Pediatr.10(Suppl. 1), 27–28 (2003).
   PubMedGoogle Scholar
• Lappalainen M. Current situation regarding toxoplasmosis in Finland. Arch. Pediatr.10(Suppl. 1), 19 (2003).
   PubMedGoogle Scholar
• Stray-Pedersen B. Prevention of congenital toxoplasmosis in Norway. Arch. Pediatr.10(Suppl. 1), 23–24 (2003).
   PubMedGoogle Scholar
• Villena I, Aubert D, Leroux B et al. Pyrimethamine–sulfadoxine treatment of congenital toxoplasmosis: follow-up of 78 cases between 1980 and 1997. Reims Toxoplasmosis Group. Scand. J. Infect. Dis.30, 295–300 (1998).
   PubMedGoogle Scholar
• Signorell LM, Seitz D, Merkel S, Berger R, Rudin C. Cord blood screening for congenital toxoplasmosis in northwestern Switzerland, 1982–1999. Pediatr. Infect. Dis. J.25(2), 123–128 (1996).
   Google Scholar
• Petersen E, Schmidt DR. Sulfadiazine and pyrimethamine in the postnatal treatment of congenital toxoplasmosis: what are the options? Expert Rev. Anti Infect. Ther.1, 175–182 (2003).
   PubMedGoogle Scholar
• Couvreur J, Nottin N, Desmonts G. La toxoplasmose congenitale traitee. Resultats cliniques et biologiques. Ann. Pediatr. (Paris)27(10), 647–652 (1980).
   PubMedGoogle Scholar
• Gilbert RE, Dunn D, Wallon M et al. Ecological comparison of the risks of mother-to-child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment period. Epidemiol. Infect.127, 113–120 (2001).
   PubMed Web of Science ®Google Scholar
• Wallon M, Kodjikian L, Binquet C et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics113(6), 1567–1572 (2004).
   PubMed Web of Science ®Google Scholar
• Mets MB, Holfels E, Boyer KM et al. Eye manifestations of congenital toxoplasmosis. Am. J. Ophthalmol.122(3), 309–324 (1996).
   PubMed Web of Science ®Google Scholar
• Wallon M, Cozon G, Ecochard R, Lewin P, Peyron F. Serological rebound in congenital toxoplasmosis: long-term follow-up of 133 children. Eur. J. Pediatr.160, 534–540 (2001).
   PubMedGoogle Scholar
• McAuley J, Boyer KM, Patel D et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin. Infect. Dis.18(1), 38–72 (1994).
   PubMed Web of Science ®Google Scholar
• McLeod R, Boyer K, Karrison T et al; the Toxoplasmosis Study Group. Outcome of treatment for congenital toxoplasmosis, 1981–2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin. Infect. Dis.42(10), 1383–1394 (2006).
   PubMed Web of Science ®Google Scholar
• Perkins ES, Schofield PB, Smith CH. Treatment of uveitis with pyrimethamine (daraprim). Br. J. Ophthalmol.40, 577–586 (1956).
   PubMedGoogle Scholar
• Rothova A, Meenken C, Buitenhuis HJ et al. Therapy for ocular toxoplasmosis. Am. J. Ophthalmol.115, 517–523 (1993).
   PubMed Web of Science ®Google Scholar
• Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am. J. Ophthalmol.134, 34–40 (2002).
   PubMed Web of Science ®Google Scholar
• Silveira C, Belfort R Jr, Muccioli C et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am. J. Ophthalmol.134, 41–46 (2002).
   PubMed Web of Science ®Google Scholar
• Schmidt DR, Høgh B, Andersen O, Hansen SH, Dalhoff K, Petersen E. Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine. Eur. J. Pediatr.165(1), 19–25 (2006).
   PubMed Web of Science ®Google Scholar
• Stramba-Badiale M, Nador F, Porta N et al. QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates. Am. Heart J.133(1), 108–111 (1997).
   PubMedGoogle Scholar
• Ferguson DJ, Huskinson-Mark J, Araujo FG, Remington JS. An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii.Int. J. Exp. Pathol.75(2), 111–116 (1994).
   PubMed Web of Science ®Google Scholar
• Gormley PD, Pavesio CE, Minnasian D, Lightman S. Effects of drug therapy on Toxoplasma cysts in an animal model of acute and chronic disease. Invest. Ophthalmol. Vis. Sci.39, 1171–1175 (1998).
   PubMed Web of Science ®Google Scholar
• Araujo FG, Khan AA, Bryskier A, Remington JS. Use of ketolides in combination with other drugs to treat experimental toxoplasmosis. J. Antimicrob. Chemother.42, 665–667 (1998).
   PubMed Web of Science ®Google Scholar
• Djurkovic-Djakovic O, Milenkovic V, Nikolic A, Bobic B, Grujic J. Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii.J. Antimicrob. Chemother.50(6), 981–987 (2002).
   PubMedGoogle Scholar
• Alves CF, Vitor RW. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil. Parasite12(2), 171–177 (2005).
   PubMedGoogle Scholar
• McFadden DC, Camps M, Boothroyd JC. Resistance as a tool in the study of old and new drug targets in Toxoplasma.Drug Resist. Updat.4(2), 79–84 (2001).
   PubMedGoogle Scholar
• Huskinson-Mark J, Araujo FG, Remington JS. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii.J. Infect. Dis.164, 170–171 (1991).
   PubMed Web of Science ®Google Scholar
• Derouin F, Caroff B, Chau F, Prokocimer P, Pocidalo JJ. Synergistic activity of clarithromycin and minocycline in an animal model of acute experimental toxoplasmosis. Antimicrob. Agents Chemother.36, 2852–2855 (1992).
   PubMedGoogle Scholar
• Caramello P, Brancale T, Forno B et al. Relapse of Toxoplasma encephalitis and susceptibility to pyrimethamine: lack of evidence of treatment-induced resistance. Antimicrob. Agents Chemother.39(10), 2371–2372 (1995).
   PubMedGoogle Scholar
• Pfefferkorn ER, Borotz SE, Nothnagel RF. Toxoplasma gondii: characterization of a mutant resistant to sulfonamides. Exp. Parasitol.74(3), 261–270 (1992).
   PubMedGoogle Scholar
• Aspinall TV, Joynson DH, Guy E, Hyde JE, Sims PF. The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis. J. Infect. Dis.185(11), 1637–1643 (2002).
   PubMedGoogle Scholar
• Peyron F, Eudes N, de Monbrison F, Wallon M, Picot S. Fitness of Toxoplasma gondii is not related to DHFR single-nucleotide polymorphism during congenital toxoplasmosis. Int. J. Parasitol.34(10), 1169–1175 (2004).
   PubMedGoogle Scholar
• Reynolds MG, Roos DS. A biochemical and genetic model for parasite resistance to antifolates. Toxoplasma gondii provides insights into pyrimethamine and cycloguanil resistance in Plasmodium falciparum.J. Biol. Chem.273(6), 3461–3469 (1998).
   PubMedGoogle Scholar